contents area
Public Health Weekly Report
detail content area
The current trends of therapeutic agents for inflammatory bowel disease and microbiota
- Date2018-05-24 20:32
- Update2018-05-24 20:32
- DivisionDivision of Strategic Planning for Emerging Infectious Diseases
- Tel043-719-7271
The current trends of therapeutic agents for inflammatory bowel disease and microbiota
Lee Myeong-Ro, Kim HyunJung, Ju Jung-Won, Lee Sang-Eun, Cho Shin-Hyeong
Division of Vectors and Parasitic Diseases, Center for Laboratory Control of Infectious Diseases, KCDC
Background: Inflammatory bowel disease (IBD) is characterized by chronic inflammation and refers to ulcerative colitis (UC) and Crohn's disease. In Crohn's disease, inflammation occurs in all body parts, from the mouth to the rectum, and UC involves inflammation only in the large intestine. IBD usually involves severe diarrhea, pain, fatigue, and weight loss. Although the etiology of IBD remains unknown, several studies have shown that the development of IBD is caused by genetic or environmental factors.
Current status: In recent years, the incidence rate of IBD has increased rapidly in Asia, as well as in Western countries. In Korea, it increased by 29.7% in 2017 compared with that in 2013. Although there are some treatments including 5-aminosalicylates and corticosteroids, their therapeutic effects are low. Recently, several studies have been conducted to identify the cause of IBD. In addition, effective therapies are being proposed. Epidemiological and experimental data show that intestinal microbial composition may be becoming a major cause of IBD. It would be useful to develop a therapeutic agents to change the composition of intestinal microorganisms or use intestinal microorganisms. From this point of view, further research will be conducted on the development of therapeutic methods for parasites such as Trichuris suis that can change the composition of intestinal microorganisms and have been stably recognized through successful clinical trials.
Future perspective: The Division of Vectors and Parasitic Diseases in the Korea Centers for Disease Control and Prevention (KCDC) will conduct research on the development of therapeutic agents using intestinal parasites or excretory secretory proteins.
Keywords: Inflammatory bowel diseases, Microbiota, Inflammation, Ulcerative colitis, Parasites
Lee Myeong-Ro, Kim HyunJung, Ju Jung-Won, Lee Sang-Eun, Cho Shin-Hyeong
Division of Vectors and Parasitic Diseases, Center for Laboratory Control of Infectious Diseases, KCDC
Background: Inflammatory bowel disease (IBD) is characterized by chronic inflammation and refers to ulcerative colitis (UC) and Crohn's disease. In Crohn's disease, inflammation occurs in all body parts, from the mouth to the rectum, and UC involves inflammation only in the large intestine. IBD usually involves severe diarrhea, pain, fatigue, and weight loss. Although the etiology of IBD remains unknown, several studies have shown that the development of IBD is caused by genetic or environmental factors.
Current status: In recent years, the incidence rate of IBD has increased rapidly in Asia, as well as in Western countries. In Korea, it increased by 29.7% in 2017 compared with that in 2013. Although there are some treatments including 5-aminosalicylates and corticosteroids, their therapeutic effects are low. Recently, several studies have been conducted to identify the cause of IBD. In addition, effective therapies are being proposed. Epidemiological and experimental data show that intestinal microbial composition may be becoming a major cause of IBD. It would be useful to develop a therapeutic agents to change the composition of intestinal microorganisms or use intestinal microorganisms. From this point of view, further research will be conducted on the development of therapeutic methods for parasites such as Trichuris suis that can change the composition of intestinal microorganisms and have been stably recognized through successful clinical trials.
Future perspective: The Division of Vectors and Parasitic Diseases in the Korea Centers for Disease Control and Prevention (KCDC) will conduct research on the development of therapeutic agents using intestinal parasites or excretory secretory proteins.
Keywords: Inflammatory bowel diseases, Microbiota, Inflammation, Ulcerative colitis, Parasites
This public work may be used under the terms of the public interest source + commercial use prohibition + nonrepudiation conditions